The DEPOT Study (Dry Eye Prescription Options for Therapy)

Exclusion Criteria

• •Active, systemic or local disease condition other than DES that causes clinically significant ocular surface irritation that could interfere with the evaluation and treatment of dry eye.
• •Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months prior to the enrollment visit:
• •* Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgery procedure)
• •* Clinically significant ocular trauma.
• •* Active ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.
• •* Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis)
• •* Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye)
• •Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis
• •Eyelid abnormalities that significantly affect lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
• •Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy)
• •Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to the distribution of the survey
• •Participation in this trial in the same patient's fellow eye.
• •Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.